A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Inclusion Criteria16

• Aged at least 18 years
• Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor.
• Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months.
• Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant:
• It cannot be due to a serious infection or a serious blood clot in your previous transplant.
• Your calculated Panel Reactive Antibody (CPRA) level must be below 50%.
• Be getting a donor kidney that meets the study's specific requirements.
• Be at low to medium risk of transplant rejection, and be scheduled to receive:
• A medication called ATG as part of your transplant procedure.
• Steroids (corticosteroids) as part of your treatment at the time of screening.
• A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice.
• Have received certain vaccines before starting the study treatment, specifically:
• Pneumococcal (S. pneumoniae)
• Meningococcal (N. meningitidis types A, C, W, Y, and B)
• Haemophilus influenzae type B
• If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor.